Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.68 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | POLG | P54098 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391225 | 1.00 | FGFR1 (0.68) | FGFR1SLC22A6ENPP1CYP3A4NT5E | |
| SCHEMBL9857536 | 0.93 | FGFR1 (0.65) | FGFR1SLC22A6ENPP1CYP3A4ABCB11 | |
| SCHEMBL9185744 | 0.89 | SLC22A6 (0.62) | FGFR1SLC22A6ENPP1CYP3A4NT5E | |
| SCHEMBL6334793 | 0.88 | FGFR1 (0.61) | FGFR1SLC22A6ENPP1CYP3A4NT5E | |
| Ammonia Solution, Strong SCHEMBL9124811 | 0.88 | SLC22A6 (0.61) | FGFR1SLC22A6ENPP1CYP3A4ABCB11 | |
| Ammonia Solution, Strong SCHEMBL9124830 | 0.88 | SLC22A6 (0.61) | FGFR1SLC22A6ENPP1CYP3A4ABCB11 | |
| SCHEMBL9417176 | 0.84 | FGFR1 (0.51) | FGFR1SLC22A6ENPP1CYP3A4NT5E | |
| SCHEMBL9685282 | 0.84 | FGFR1 (0.53) | FGFR1SLC22A6ENPP1CYP3A4ADORA2A | |
| SCHEMBL9417160 | 0.83 | SLC22A6 (0.50) | FGFR1SLC22A6ENPP1CYP3A4NT5E | |
| SCHEMBL9857534 | 0.83 | FGFR1 (0.57) | FGFR1SLC22A6ENPP1CYP3A4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829565-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2021-06-09 | — | — | EP | claimed |
| WO-2020025488-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2020-02-06 | — | — | WO | claimed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | claimed |
| EP-1532157-A2 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | Metabasis Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| EP-0319228-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1994-11-02 | — | — | EP | claimed |
| US-5247085-A | Phosphonate containing purine compounds | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | claimed |
| EP-0319228-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-06-07 | — | — | EP | claimed |
| US-20210292353-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-09-23 | — | — | US | disclosed |
| EP-3829565-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020025488-A1 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | Karlsruher Institut für Technologie (DE) | 2020-02-06 | — | — | WO | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
| EP-0631583-A1 | ANTIVIRAL PHOSPHONIC ACID DERIVATIVES OF PURINE ANALOGUES | SMITHKLINE BEECHAM PLC (GB) | 1995-01-04 | — | — | EP | disclosed |
| WO-1993019075-A1 | ANTIVIRAL PHOSPHONIC ACID DERIVATIVES OF PURINE ANALOGUES | SMITHKLINE BEECHAM PLC (GB) | 1993-09-30 | — | — | WO | disclosed |
| US-5247085-A | Phosphonate containing purine compounds | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | disclosed |
| WO-1992009611-A1 | PHARMACEUTICALS | BEECHAM GROUP PLC (GB) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | FGFR1 3580/4885SLC22A6 432/4885ENPP1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.